DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Sacubitril is an investigational drug.
There have been 48 clinical trials for Sacubitril. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2016.
The most common disease conditions in clinical trials are Heart Failure, Hypertension, and Diabetes Mellitus. The leading clinical trial sponsors are Novartis Pharmaceuticals, Brigham and Women's Hospital, and National Heart Centre Singapore.
There are forty-two US patents protecting this investigational drug and four hundred and seventy-four international patents.
Recent Clinical Trials for Sacubitril
|Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC||Novartis Pharmaceuticals||Phase 4|
|Sacubitril/Valsartan in Left Ventricular Assist Device Recipients||University of Zagreb||Phase 4|
|The Effects of Natriuretic Peptide Augmentation on Cardiometabolic Health in African Americans||University of Alabama at Birmingham||Phase 2|
Top disease conditions for Sacubitril
Top clinical trial sponsors for Sacubitril
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Sacubitril||See Pricing||Organic compounds||INTRA-CELLULAR THERAPIES, INC. (New York, NY)||See Pricing|
|Sacubitril||See Pricing||Synthetic linear apelin mimetics for the treatment of heart failure||NOVARTIS AG (Basel, CH)||See Pricing|
|Sacubitril||See Pricing||Neprilysin inhibitors||THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Sacubitril||World Intellectual Property Organization (WIPO)||2016022836||2034-08-07||See Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|